BACKGROUND AND PURPOSE: Inhaled glucocorticoid (ICS)/long-acting β2 -adrenoceptor agonist (LABA) combination therapy is a recommended treatment option for patients with moderate/severe asthma in whom adequate control cannot be achieved by an ICS alone. Previously, we discovered that LABAs can augment dexamethasone-inducible gene expression and proposed that this effect may explain how these two drugs interact to deliver superior clinical benefit. Herein, we extended that observation by analysing, pharmacodynamically, the effect of the LABA, indacaterol, on glucocorticoid receptor (GR)-mediated gene transcription induced by seven ligands with intrinsic activity values that span the spectrum of full agonism to antagonism. EXPERIMENTAL APPROACH: BEAS-2B human airway epithelial cells stably transfected with a 2× glucocorticoid response element luciferase reporter were used to model gene transcription together with an analysis of several glucocorticoid-inducible genes. KEY RESULTS: Indacaterol augmented glucocorticoid-induced reporter activation in a manner that was positively related to the intrinsic activity of the GR agonist. This effect was demonstrated by an increase in response maxima without a change in GR agonist affinity or efficacy. Indacaterol also enhanced glucocorticoid-inducible gene expression. However, the magnitude of this effect was dependent on both the GR agonist and the gene of interest. CONCLUSIONS AND IMPLICATIONS: These data suggest that indacaterol activates a molecular rheostat, which increases the transcriptional competency of GR in an agonist- and gene-dependent manner without apparently changing the relationship between fractional GR occupancy and response. These findings provide a platform to rationally design ICS/LABA combination therapy that is based on the generation of agonist-dependent gene expression profiles in target and off-target tissues.
BACKGROUND AND PURPOSE: Inhaled glucocorticoid (ICS)/long-acting β2 -adrenoceptor agonist (LABA) combination therapy is a recommended treatment option for patients with moderate/severe asthma in whom adequate control cannot be achieved by an ICS alone. Previously, we discovered that LABAs can augment dexamethasone-inducible gene expression and proposed that this effect may explain how these two drugs interact to deliver superior clinical benefit. Herein, we extended that observation by analysing, pharmacodynamically, the effect of the LABA, indacaterol, on glucocorticoid receptor (GR)-mediated gene transcription induced by seven ligands with intrinsic activity values that span the spectrum of full agonism to antagonism. EXPERIMENTAL APPROACH: BEAS-2B human airway epithelial cells stably transfected with a 2× glucocorticoid response element luciferase reporter were used to model gene transcription together with an analysis of several glucocorticoid-inducible genes. KEY RESULTS:Indacaterol augmented glucocorticoid-induced reporter activation in a manner that was positively related to the intrinsic activity of the GR agonist. This effect was demonstrated by an increase in response maxima without a change in GR agonist affinity or efficacy. Indacaterol also enhanced glucocorticoid-inducible gene expression. However, the magnitude of this effect was dependent on both the GR agonist and the gene of interest. CONCLUSIONS AND IMPLICATIONS: These data suggest that indacaterol activates a molecular rheostat, which increases the transcriptional competency of GR in an agonist- and gene-dependent manner without apparently changing the relationship between fractional GR occupancy and response. These findings provide a platform to rationally design ICS/LABA combination therapy that is based on the generation of agonist-dependent gene expression profiles in target and off-target tissues.
Authors: Aaron L Miller; M Scott Webb; Alicja J Copik; Yongxin Wang; Betty H Johnson; Raj Kumar; E Brad Thompson Journal: Mol Endocrinol Date: 2005-04-07
Authors: M Profita; R Gagliardo; R Di Giorgi; F Pompeo; M Gjomarkaj; G Nicolini; J Bousquet; A M Vignola Journal: Allergy Date: 2005-03 Impact factor: 13.146
Authors: Gail M Gauvreau; Louis-Philippe Boulet; Richard Leigh; Donald W Cockcroft; Kieran J Killian; Beth E Davis; Francine Deschesnes; Richard M Watson; Veronica Swystun; Carina Kärrman Mårdh; Peter Wessman; Carin Jorup; Magnus Aurivillius; Paul M O'Byrne Journal: Am J Respir Crit Care Med Date: 2015-01-15 Impact factor: 21.405
Authors: E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar Journal: Eur Respir J Date: 2008-01 Impact factor: 16.671
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Richard Leigh; Mahmoud M Mostafa; Elizabeth M King; Christopher F Rider; Suharsh Shah; Curtis Dumonceaux; Suzanne L Traves; Andrew McWhae; Tyler Kolisnik; Cora Kooi; Donna M Slater; Margaret M Kelly; Mark Bieda; Anna Miller-Larsson; Robert Newton Journal: Pharmacol Res Perspect Date: 2016-07-12
Authors: Diego S Coutinho; Edna A Anjos-Valotta; Caio V M F do Nascimento; Ana Lucia A Pires; Marcelo H Napimoga; Vinícius F Carvalho; Rafael C Torres; Patrícia M R E Silva; Marco A Martins Journal: Front Immunol Date: 2017-06-30 Impact factor: 7.561
Authors: Neil D Theise; Anthony R Arment; Dimple Chakravarty; John M H Gregg; Ira M Jacobson; Kie Hoon Jung; Sujit S Nair; Ashutosh K Tewari; Archie W Thurston; John Van Drie; Jonna B Westover Journal: Cell Cycle Date: 2020-12-11 Impact factor: 4.534